Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
University of California Irvine
Search grants from University of California Irvine
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Optimizing motor training in Parkinson disease through neural mechanisms
Massively Parallel Characterization of Cis-Regulatory Elements in the Brain
The molecular mechanisms by which mammalian Fused regulates motile cilia function
Lentiviral Transgenesis of the Aqueous Outflow Tract
BMP-1-like protease effects on growth factors &hormones
Recently added grants:
Top-down modulation of visual processing: mechanisms and functions
Deep Learning Approaches for Personalized Modeling and Forecasting of Glaucomatous Changes
Structure, function and aggregation of lens ?-crystallins by CryoEM
Lens epithelial cell heterogeneity during development
Molecular, cellular, anatomical and neurobiological investigation of melanopsin-expressing corneal innervation, and its role in pain and photophobia
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CA075019-006
Application #
6828778
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2003
Total Cost
Indirect Cost
Institution
Name
University of California Irvine
Department
Type
DUNS #
City
State
Country
Zip Code
Related projects
NIH 2003
N01 CA
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
/ University of California Irvine
NIH 2002
N01 CA
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
/ University of California Irvine
Publications
Beeram, M; Tan, Q-T N; Tekmal, R R et al.
(2007)
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
Ann Oncol 18:1323-8
Comments
Be the first to comment on this grant